SCHEMBL20262364

SCHEMBL20262364

CN1C(=O)[C@@H](NC(=O)c2ncn(Cc3ccccc3F)n2)CCc2nn(C)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30096515 1.00 RIPK1 (1.00) RIPK1
SCHEMBL20276644 0.88 RIPK1 (1.00) RIPK1
SCHEMBL20262368 0.88 RIPK1 (1.00) RIPK1
SCHEMBL21221013 0.84 RIPK1 (1.00) RIPK1
SCHEMBL21220803 0.84 RIPK1 (1.00) RIPK1
SCHEMBL21220978 0.84 RIPK1 (1.00) RIPK1
SCHEMBL21220805 0.84 RIPK1 (1.00) RIPK1
SCHEMBL20262313 0.84 RIPK1 (1.00) RIPK1
SCHEMBL21220905 0.84 RIPK1 (1.00) RIPK1
SCHEMBL21220896 0.84 RIPK1 (1.00) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4095138-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF F. Hoffmann-La Roche AG (CH) 2022-11-30 — — EP claimed
US-11072607-B2 Inhibitors of RIP1 kinase and methods of use thereof GENENTECH, INC. (US) 2021-07-27 — — US claimed
US-20180170927-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-21 — — US claimed
EP-4095138-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF F. Hoffmann-La Roche AG (CH) 2022-11-30 — — EP disclosed
EP-3555093-B1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2022-09-21 — — EP disclosed
US-11072607-B2 Inhibitors of RIP1 kinase and methods of use thereof GENENTECH, INC. (US) 2021-07-27 — — US disclosed
US-11072607-B2 Inhibitors of RIP1 kinase and methods of use thereof GENENTECH, INC. (US) 2021-07-27 — — US disclosed
EP-3555093-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF H. Hoffnabb-La Roche Ag (CH) 2019-10-23 — — EP disclosed
US-20180170927-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-21 — — US disclosed
US-20180170927-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-21 — — US disclosed
WO-2018109097-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2018-06-21 — — WO disclosed
US-20180170927-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11072607-B2 Inhibitors of RIP1 kinase and methods of use thereof RIPK1, RIPK2, RIPK4 RIPK1 1/4885
US-20180170927-A1 INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF RIPK1, RIPK2, RIPK4 RIPK1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback